Timegadine is a novel anti-inflammatory agent used to inhibit prostaglandin synthetase, cyclooxygenase (COX), and lipoxygenase; it significantly suppresses both primary and secondary lesions in adjuvant arthritis when administered orally at doses of 10–30 mg/kg daily; it specifically prevents swelling development in the non-injected paw in adjuvant-induced arthritis models, showing efficacy comparable to cyclophosphamide.